NCT02833610 2026-02-18
A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
Massachusetts General Hospital
Phase 2 Completed
Clinical Trials
27 trialsNCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT04067726 2025-10-16
TRIDENT
Washington University School of Medicine
Phase 2 Active not recruiting
NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
NCT04907539 2025-04-16
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Redx Pharma Ltd
Phase 2 Completed
NCT03792763 2025-02-11
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT06749886 2024-12-27
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT03869762 2024-09-25
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT03620019 2024-08-12
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02470091 2024-01-22
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Children's Oncology Group
Phase 2 Completed
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT03732495 2022-03-29
LENVOS
Centre Leon Berard
Phase 2 Unknown
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT01951586 2021-10-25
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen
Phase 2 Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT03620149 2021-01-06
REDUCE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT03532087 2020-01-18
PERIDENO
Borstkanker Onderzoek Groep
Phase 2 Withdrawn
NCT01545648 2020-01-02
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01952054 2019-11-22
Denosumab for Breast Cancer With Bone Mets
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT03605199 2019-08-26
Denosumab in Subjects With Giant Cell Rich Tumors of Bone
Leiden University Medical Center
Phase 2 Unknown
NCT01864798 2018-11-27
D-Beyond
Jules Bordet Institute
Phase 2 Terminated
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT00091832 2014-01-28
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Amgen
Phase 2 Completed
NCT00104650 2011-01-24
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Amgen
Phase 2 Completed